Document is current

Article History

Accepted: 4 April 2025

First Online: 16 May 2025

Competing interests

: M.Y. receives grant/research support (to Johns Hopkins) from Bristol-Myers Squibb, Exelixis, Incyte and Genentech; receives honoraria from Exelixis, AstraZeneca, Replimune, Hepion, Lantheus, Genentech and Incyte; is the co-inventor of a patent related to neoantigen vaccines; and is a co-founder with equity of Adventris Pharmaceuticals. N.Z. receives grant/research support (to Johns Hopkins) from Bristol-Myers Squibb; receives honoraria from Genentech; is the co-inventor of patents related to neoantigen vaccines; and is a co-founder with equity of Adventris Pharmaceuticals. E.M.J. reports other support from Abmeta and Adventris; personal fees from Dragonfly, Neuvogen, CPRIT, Surge Tx, Mestag, Medical Home Group and HDTbio; grants from Lustgarten, Genentech, BMS, NeoTx and Break Through Cancer; is a founder of and holds equity in Adventris Pharmaceuticals; and serves as a consultant to the entity. Further, Adventris Pharmaceuticals has licensed a technology described in this study from the Johns Hopkins University. As a result of that agreement, E.M.J. and the University are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.